ScreenerHero

HYPDHyperion DeFi Inc. Common Stock

NAS · US · Healthcare · Biotechnology · hyperiondefi.com
3.180USD+4.61%Mkt Cap: 49.42M $P/E: —

Hyperion DeFi, Inc., a DeFi company, engages in building on Hyperliquid. It operates through two segments: Ophthalmic Technology and Digital Assets. The company focuses on the long-term strategic treasury of HYPE tokens …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap49.42M $
Enterprise Value48.07M $
Revenue (TTM)1.40M $
Gross Profit510.17K $
Net Income (TTM)-45.31M $
Revenue/Share0.1430 USD
Last Price3.180 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees9
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue34.32
P/S34.84
P/B0.61
EPS (TTM)-3.97
EPS (Forward)—
52W Range
2.3407% of range15.00
52W High15.00 USD
52W Low2.340 USD
Profitability
Gross Margin62.72%
Oper. Margin-757.51%
EBITDA Margin0.00%
Profit Margin-5570.61%
ROE-110.36%
ROA-87.54%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-14.77M $
CapEx (TTM)71.95M $
FCF Margin-1056.90%
FCF Yield-29.96%
Net Debt-725.30K $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.21
Current Ratio2.34
Quick Ratio1.82
Book Value/Sh5.118 USD
Cash/Share0.6200 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:80
Split DateFeb 3, 2025
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)7.200 USD
Upside (mean)+126.4%
Target Range7.100 USD – 7.300 USD
$7.100+126.4% to mean$7.300
# Analysts2
Ownership
Shares Out.15.54M
Float13.70M
Insiders13.49%
Institutions18.00%
Short Interest
Short Ratio5.8d
Short % Float10.63%
Short % Out.10.29%
Shares Short1.56M
Short (prev mo.)1.35M
Technical
SMA 502.897 (+9.8%)
SMA 2003.537 (-10.1%)
Beta2.50
S&P 52W Chg18.16%
Avg Vol (30d)286.87K
Avg Vol (10d)458.02K
Technical Indicators
RSI (14)63.2
MACD0.0156
MACD Signal-0.0579
MACD Hist.+0.0735
BB Upper3.066 USD
BB Middle2.691 USD
BB Lower2.315 USD
BB Width27.91%
ATR (14)0.2453 USD
Vol Ratio (20d)2.47x